Supernus Pharmaceuticals Stock In The News

SUPN Stock  USD 31.26  0.09  0.29%   
Our overall analysis of Supernus Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Supernus Pharmaceuticals. The specific impact of Supernus Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Supernus Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Supernus Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Supernus Pharmaceuticals Backtesting and Supernus Pharmaceuticals Hype Analysis.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

Supernus Pharmaceuticals Today Top News and Investor Outlook

Yahoo News
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
https://finance.yahoo.com/news/q4-earnings-recap-supernus-pharmaceuticals-090114031.html
 Bullish
Yahoo News
3 Small-Cap Stocks Skating on Thin Ice
https://finance.yahoo.com/news/3-small-cap-stocks-skating-130052729.html
 Bullish
Yahoo News
Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts
https://finance.yahoo.com/news/supernus-pharmaceuticals-inc-supn-among-002452299.html
 Bullish
Macroaxis News: globenewswire.com
Supernus to Participate in Two Upcoming Investor Conferences
https://www.globenewswire.com/news-release/2025/03/04/3036999/19871/en/Supernus-to-Participate-in-Two-Upcoming-Investor-Conferences.html
 Bullish
Yahoo News
Supernus to Participate in Two Upcoming Investor Conferences
https://finance.yahoo.com/news/supernus-participate-two-upcoming-investor-213000546.html
 Bullish
Yahoo News
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
https://finance.yahoo.com/news/q4-earnings-outperformers-corcept-nasdaq-090617793.html
 Bullish
Yahoo News
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
https://finance.yahoo.com/news/branded-pharmaceuticals-stocks-q4-review-090318015.html
 Bullish
Yahoo News
Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?
https://finance.yahoo.com/news/does-market-low-tolerance-supernus-112941762.html
 Bullish
Yahoo News
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now?
https://finance.yahoo.com/news/supernus-pharmaceuticals-inc-supn-best-171640328.html
 Bullish
Yahoo News
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
https://finance.yahoo.com/news/supernus-participate-td-cowen-45th-133000218.html
 Bullish

Supernus Pharmaceuticals Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Supernus and other traded companies coverage with news coverage. We help investors stay connected with Supernus headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Supernus Stock performance. Please note that trading solely based on the Supernus Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Supernus Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Supernus Pharmaceuticals investors visualize upcoming and past events in order to time the market based on Supernus Pharmaceuticals noise-free hype analysis.
Supernus Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Supernus earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Supernus Pharmaceuticals that are available to investors today. That information is available publicly through Supernus media outlets and privately through word of mouth or via Supernus internal channels. However, regardless of the origin, that massive amount of Supernus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Supernus Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Supernus Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Supernus Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Supernus Pharmaceuticals alpha.

Supernus Largest EPS Surprises

Earnings surprises can significantly impact Supernus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2016-05-03
2016-03-310.090.08-0.0111 
2015-08-04
2015-06-300.020.030.0150 
2017-05-09
2017-03-310.220.19-0.0313 
2015-05-05
2015-03-31-0.010.020.03300 
2024-08-06
2024-06-300.310.360.0516 
2016-08-02
2016-06-300.130.180.0538 
View All Earnings Estimates

Supernus Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Supernus Pharmaceuticals Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
news
12th of March 2025
Is Supernus Pharmaceuticals Seeing Increased Institutional Activity
at kalkinemedia.com 
Yahoo News
7th of March 2025
Disposition of 2625 shares by Frank Mottola of Supernus Pharmaceuticals subject to Rule 16...
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
4th of March 2025
Supernus Pharmaceuticals Inc Announces Participation in March Investor Conferences
at gurufocus.com 
Gurufocus Stories at Macroaxis
27th of February 2025
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
at gurufocus.com 
Yahoo News
26th of February 2025
Supernus Pharmaceuticals Inc Q4 2024 Earnings Call Highlights Strong Revenue Growth ...
at finance.yahoo.com 
Yahoo News
25th of February 2025
Supernus Pharmaceuticals Delivers Strong Q4 Numbers
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
20th of February 2025
Supernus Pharmaceuticals Inc Shares Up 1.52 percent on Feb 20
at gurufocus.com 
news
6th of February 2025
Meritage Portfolio Management Has 1.74 Million Position in Supernus Pharmaceuticals, Inc.
at thelincolnianonline.com 
Macroaxis News
27th of January 2025
Disposition of 2573 shares by Padmanabh Bhatt of Supernus Pharmaceuticals at 29.61 subject...
at MacroaxisInsider 

Supernus Pharmaceuticals Investors Sentiment

The influence of Supernus Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Supernus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Supernus Pharmaceuticals' public news can be used to forecast risks associated with an investment in Supernus. The trend in average sentiment can be used to explain how an investor holding Supernus can time the market purely based on public headlines and social activities around Supernus Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Supernus Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Supernus Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Supernus Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Supernus Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Supernus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Supernus Pharmaceuticals' short interest history, or implied volatility extrapolated from Supernus Pharmaceuticals options trading.
When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
14.447
Earnings Share
1.32
Revenue Per Share
12.011
Quarterly Revenue Growth
0.06
Return On Assets
0.029
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.